High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report

Anaplastic lymphoma kinase (ALK) fusions have been identified in approximately 5% of non-small cell lung cancer (NSCLC) cases. ALK-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for patients with ALK-positive (ALK+) advanced NSCLC. Along with widespread use of next-generatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Duan, Peng, Guan, Yan, Chen, Qing, Grenda, Anna, Christopoulos, Petros, Denis, Marc G., Guo, Qisen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
iMDT Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825656/
https://www.ncbi.nlm.nih.gov/pubmed/35242631
http://dx.doi.org/10.21037/tlcr-21-1039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825656/
https://www.ncbi.nlm.nih.gov/pubmed/35242631
http://dx.doi.org/10.21037/tlcr-21-1039

Ejemplares similares